Aptevo Therapeutics (FRA:AP82) Stock Based Compensation: €-0.02 Mil (TTM As of Mar. 2026)


FRA:AP82 Aptevo Therapeutics Inc FRA:AP82
29 GF Score
Price €65,970.00
! 1 Warning Sign
View Full Analysis

What is Aptevo Therapeutics Stock Based Compensation?

Aptevo Therapeutics FRA:AP82 29 Stock Based Compensation is €-0.02 Mil as of Mar. 2026. GuruFocus rates FRA:AP82 with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Aptevo Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was €0.05 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.02 Mil.

Aptevo Therapeutics Stock Based Compensation Related Terms

Aptevo Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Aptevo Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aptevo Therapeutics Stock Based Compensation Chart

Aptevo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.45 1.70 2.01 1.02 0.08

Aptevo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 -0.14 0.07 0.00 0.05
FRA:AP82
29GF Score
Aptevo Therapeutics Inc FRA:AP82
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aptevo Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.02 Mil.

What does a Stock Based Compensation of €-0.02 Mil mean?
Aptevo Therapeutics (FRA:AP82) has a Stock Based Compensation of €-0.02 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Aptevo Therapeutics and its competitors.
Is Aptevo Therapeutics' Stock Based Compensation too high?
Aptevo Therapeutics' current Stock Based Compensation is €-0.02 Mil. Overall, Aptevo Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aptevo Therapeutics' Stock Based Compensation compare to ENVB and ADIL?
Aptevo Therapeutics' Stock Based Compensation of €-0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Aptevo Therapeutics and its competitors. Aptevo Therapeutics's current Stock Based Compensation is €-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptevo Therapeutics stock overvalued right now?
Aptevo Therapeutics (FRA:AP82) has a current Stock Based Compensation of €-0.02 Mil. The current Stock Based Compensation is €-0.02 Mil. Aptevo Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Aptevo Therapeutics (FRA:AP82), the current Stock Based Compensation is €-0.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aptevo Therapeutics Business Description

Other Exchanges APVO:USA
Address 2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
29GF Score

Get the complete analysis for FRA:AP82

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65,970.00
Price